Dupilumab treatment decreases MBC2s, correlating with reduced IgE levels in pediatric atopic dermatitis

A preference for type 2 immunity plays a central role in the pathogenesis of atopic dermatitis (AD). Dupilumab, an mAb targeting the IL-4 receptor α (IL-4Rα) subunit, inhibits IL-4 and IL-13 signaling. These cytokines contribute significantly to IgE class switch recombination in B cells, critical in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2024-11, Vol.154 (5), p.1333-1338.e4
Hauptverfasser:	Starrenburg, Margot E., Bel Imam, Manal, Lopez, Juan F., Buergi, Laura, Nguyen, N. Tan, Nouwen, Anouk E.M., Arends, Nicolette J.T., Caspers, Peter J., Akdis, Mübeccel, Pasmans, Suzanne G.M.A., van de Veen, Willem
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Antibodies, Monoclonal, Humanized - therapeutic use atopic dermatitis Child Child, Preschool cyclosporine Cyclosporine - therapeutic use Dermatitis, Atopic - blood Dermatitis, Atopic - drug therapy Dermatitis, Atopic - immunology dupilumab Female Humans IgE IL-4 signaling Immunoglobulin E - blood Immunoglobulin E - immunology Interleukin-4 Receptor alpha Subunit - antagonists & inhibitors Interleukin-4 Receptor alpha Subunit - immunology Male MBC2 memory B cells Memory B Cells - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!